Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate Cancer (CRPC)”

231 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 231 results

Testing effectiveness (Phase 2)Study completedNCT02952534
What this trial is testing

Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 277
Testing effectiveness (Phase 2)Study completedNCT01599793
What this trial is testing

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

Who this might be right for
Bone MetastasesCastrate-resistant Prostate CancerRecurrent Prostate Cancer+1 more
University of Chicago 19
Testing effectiveness (Phase 2)Study completedNCT00770848
What this trial is testing

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Who this might be right for
CancerCastrate-Resistant Prostate CancerMestastatic Prostate Cancer+1 more
Amgen 162
Testing effectiveness (Phase 2)Study completedNCT01206036
What this trial is testing

CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)

Who this might be right for
Prostatic Neoplasms
Central European Society for Anticancer Drug Research 19
Testing effectiveness (Phase 2)Study completedNCT01106352
What this trial is testing

Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
Bone MetastasesCastration-Resistant Prostate Cancer
Bayer 70
Testing effectiveness (Phase 2)Study completedNCT01046916
What this trial is testing

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

Who this might be right for
Prostate Cancer
Millennium Pharmaceuticals, Inc. 38
Testing effectiveness (Phase 2)Looking for participantsNCT06610825
What this trial is testing

Castrate Resistant Prostate Cancer Enhertu Therapy

Who this might be right for
Prostate Cancer MetastaticProstate CancerCRPC
Washington D.C. Veterans Affairs Medical Center 60
Early research (Phase 1)Study completedNCT00959959
What this trial is testing

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
LTN PHARMACEUTICALS, INC. 49
Testing effectiveness (Phase 2)WithdrawnNCT02793765
What this trial is testing

Docetaxel Followed by Provenge in Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
The University of Texas Health Science Center, Houston
Testing effectiveness (Phase 2)Study completedNCT01942837
What this trial is testing

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute 67
Very early researchStudy completedNCT02113657
What this trial is testing

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 30
Large-scale testing (Phase 3)Study completedNCT00988208
What this trial is testing

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Celgene 1,059
Large-scale testing (Phase 3)Ended earlyNCT01522443
What this trial is testing

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate CancerCastration Resistant Prostate CancerPain+1 more
Exelixis 119
Large-scale testing (Phase 3)Ended earlyNCT02057666
What this trial is testing

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Ipsen 146
Post-approval studies (Phase 4)Active Not RecruitingNCT04108208
What this trial is testing

Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 75
Testing effectiveness (Phase 2)Ended earlyNCT02685267
What this trial is testing

Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Prostate Cancer Clinical Trials Consortium 9
Testing effectiveness (Phase 2)Ended earlyNCT03261336
What this trial is testing

Oral Calcitriol With Ketoconazole in CRPC

Who this might be right for
Castration-resistant Prostate Cancer
Donald Trump, MD 1
Not applicableStudy completedNCT03315260
What this trial is testing

Treatment Satisfaction With Ra-223 in Japan

Who this might be right for
Prostatic Neoplasms
Bayer 85
Testing effectiveness (Phase 2)Study completedNCT01026623
What this trial is testing

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerProstate AdenocarcinomaRecurrent Prostate Carcinoma+1 more
National Cancer Institute (NCI) 16
Early research (Phase 1)Study completedNCT02814669
What this trial is testing

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Who this might be right for
Castrate-Resistant Prostate Cancer
Hoffmann-La Roche 45
Load More Results